Classification of the four main types of lung cancer using a microRNA-based diagnostic assay.

For patients with primary lung cancer, accurate determination of the tumor type significantly influences treatment decisions. However, techniques and methods for lung cancer typing lack standardization. In particular, owing to limited tumor sample amounts and the poor quality of some samples, the classification of primary lung cancers using small preoperative biopsy specimens presents a diagnostic challenge using current tools. We previously described a microRNA-based assay (miRview squamous; Rosetta Genomics Ltd., Rehovot, Israel) that accurately differentiates between squamous and nonsquamous non-small cell lung cancer. Herein, we describe the development and validation of an assay that differentiates between the four main types of lung cancer: squamous cell carcinoma, nonsquamous non-small cell lung cancer, carcinoid, and small cell carcinoma. The assay, miRview lung (Rosetta Genomics Ltd.), is based on the expression levels of eight microRNAs, measured using a sensitive quantitative RT-PCR platform. It was validated on an independent set of 451 samples, more than half of which were preoperative cytologic samples (fine-needle aspiration and bronchial brushing and washing). The assay returned a result for more than 90% of the samples with overall accuracy of 94% (95% CI, 91% to 96%), with similar performance observed in pathologic and cytologic samples. Thus, miRview lung is a simple and reliable diagnostic assay that offers an accurate and standardized classification tool for primary lung cancer using pathologic and cytologic samples.

[1]  K. Jöckel,et al.  Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. , 2006, Lung cancer.

[2]  A R Feinstein,et al.  Observer Variability in the Histopathologic Diagnosis of Lung Cancer1, 2 , 2015 .

[3]  R. A. Robinson,et al.  Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. , 2004, Journal of the National Cancer Institute.

[4]  L. Seymour,et al.  Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. , 2006, Clinical lung cancer.

[5]  R. Tonelli,et al.  Proteomic analysis of formalin-fixed, paraffin-embedded lung neuroendocrine tumor samples from hospital archives. , 2011, Journal of proteomics.

[6]  T. Ha.  MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease , 2011, Immune network.

[7]  H. Benjamin,et al.  Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach , 2010, Clinical Cancer Research.

[8]  R. Herbst,et al.  Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Gideon Rechavi,et al.  Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Yatabe,et al.  Molecular and Cellular Pathobiology Mir-375 Is Activated by Ash1 and Inhibits Yap1 in a Lineage-dependent Manner in Lung Cancer , 2022 .

[12]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[13]  Q. K. Li,et al.  Cytologic diagnosis and differential diagnosis of lung carcinoid tumors a retrospective study of 63 cases with histologic correlation , 2010, Cancer cytopathology.

[14]  A. Schetter,et al.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. , 2010, Carcinogenesis.

[15]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[16]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[18]  Iris Barshack,et al.  MiR‐92b and miR‐9/9* Are Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors , 2008, Brain pathology.

[19]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[20]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[21]  Thomas Tuschl,et al.  miRNAs in human cancer , 2011, The Journal of pathology.

[22]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[23]  John S Mattick,et al.  Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7* , 2009, Journal of Biological Chemistry.

[24]  A. Sandler.  Bevacizumab in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[25]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Guanghai Yang,et al.  MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). , 2010, Clinica chimica acta; international journal of clinical chemistry.

[27]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[28]  R. Aharonov,et al.  MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.

[29]  E. Wang,et al.  Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells , 2010, BMC Cancer.

[30]  A. Schetter,et al.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.

[31]  Bo Jian,et al.  Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens , 2009, Diagnostic cytopathology.

[32]  H. Asamura,et al.  Immunohistochemical expression of TTF‐1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity , 2007, Pathology international.

[33]  Shu Zheng,et al.  Epidermal growth factor receptor-regulated miR-125a-5p – a metastatic inhibitor of lung cancer , 2009, The FEBS journal.

[34]  D. Burstein,et al.  P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.

[35]  Avrum Spira,et al.  miR-129 regulates cell proliferation by downregulating Cdk6 expression. , 2010, Cell cycle.

[36]  Anne-Marie C. Dingemans,et al.  MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer , 2011, PloS one.

[37]  C. Gomez-Fernandez,et al.  P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples , 2009, Cancer.